Collegium Pharmaceutical (COLL) Cash from Financing Activities (2014 - 2026)

Collegium Pharmaceutical's Cash from Financing Activities history runs 13 years deep, the most recent figure standing at -$21.3 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 15.43% year-over-year to -$21.3 million in Q1 2026; TTM through Mar 2026 was -$106.4 million, a 235.57% decrease from a year earlier, with the FY2025 full-year figure at -$110.2 million, down 81.91% from the prior year.
• Cash from Financing Activities advanced to -$21.3 million in Q1 2026 per COLL's latest filing, from -$21.8 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $517.8 million in Q1 2022 and bottomed at -$114.2 million in Q2 2024.
• The 5-year median for Cash from Financing Activities is -$25.8 million (2022), against an average of $6.1 million.
• Across the five-year window, Cash from Financing Activities jumped 4614.86% in 2022 and slumped 205.3% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at -$25.8 million in 2022, then tumbled by 162.66% to -$67.8 million in 2023, then soared by 39.14% to -$41.3 million in 2024, then soared by 47.14% to -$21.8 million in 2025, then grew by 2.2% to -$21.3 million in 2026.
• Per Business Quant, the three latest COLL Cash from Financing Activities figures stand at -$21.3 million (Q1 2026), -$21.8 million (Q4 2025), and -$14.8 million (Q3 2025).